GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VivoSim Labs Inc (FRA:4OR) » Definitions » Cyclically Adjusted Revenue per Share

VivoSim Labs (FRA:4OR) Cyclically Adjusted Revenue per Share : €10.16 (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is VivoSim Labs Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

VivoSim Labs's adjusted revenue per share for the three months ended in Mar. 2025 was €0.029. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €10.16 for the trailing ten years ended in Mar. 2025.

During the past 12 months, VivoSim Labs's average Cyclically Adjusted Revenue Growth Rate was -2.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -1.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of VivoSim Labs was -1.20% per year. The lowest was -1.20% per year. And the median was -1.20% per year.

As of today (2025-06-30), VivoSim Labs's current stock price is €3.492. VivoSim Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €10.16. VivoSim Labs's Cyclically Adjusted PS Ratio of today is 0.34.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of VivoSim Labs was 6.59. The lowest was 0.22. And the median was 1.87.


VivoSim Labs Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for VivoSim Labs's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VivoSim Labs Cyclically Adjusted Revenue per Share Chart

VivoSim Labs Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 5.91 6.05 6.03 10.16

VivoSim Labs Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.03 5.89 4.92 5.43 10.16

Competitive Comparison of VivoSim Labs's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, VivoSim Labs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VivoSim Labs's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VivoSim Labs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where VivoSim Labs's Cyclically Adjusted PS Ratio falls into.


;
;

VivoSim Labs Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, VivoSim Labs's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.029/134.9266*134.9266
=0.029

Current CPI (Mar. 2025) = 134.9266.

VivoSim Labs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.789 100.684 1.057
201509 0.696 100.392 0.935
201512 0.782 99.792 1.057
201603 1.309 100.470 1.758
201606 2.060 101.688 2.733
201609 3.160 101.861 4.186
201612 2.585 101.863 3.424
201703 1.749 102.862 2.294
201706 2.021 103.349 2.639
201709 2.567 104.136 3.326
201712 2.179 104.011 2.827
201803 1.944 105.290 2.491
201806 1.272 106.317 1.614
201809 1.701 106.507 2.155
201812 1.415 105.998 1.801
201903 1.209 107.251 1.521
201906 1.117 108.070 1.395
201909 2.057 108.329 2.562
201912 0.493 108.420 0.614
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 1.879 121.301 2.090
202206 0.000 125.017 0.000
202209 0.107 125.227 0.115
202212 0.171 125.222 0.184
202303 0.208 127.348 0.220
202306 0.095 128.729 0.100
202309 0.000 129.860 0.000
202312 0.007 129.419 0.007
202403 0.032 131.776 0.033
202406 0.029 132.554 0.030
202409 0.018 133.029 0.018
202412 0.015 133.157 0.015
202503 0.029 134.927 0.029

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


VivoSim Labs  (FRA:4OR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

VivoSim Labs's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.492/10.16
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of VivoSim Labs was 6.59. The lowest was 0.22. And the median was 1.87.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


VivoSim Labs Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of VivoSim Labs's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


VivoSim Labs Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VivoSim Labs Inc (FRA:4OR) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.

VivoSim Labs Headlines

No Headlines